Home > Insider Trading > Filing (0001012975-14-000787)

Filing Details

Accession Number:: 0001012975-14-000787
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-12-10 19:26:56
Reporting Period:: 2014-12-08

Filing Date:: 2014-12-10
Accepted Time:: 2014-12-10 19:26:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1262104	Mei Pharma Inc.	MEIP	Pharmaceutical Preparations (2834)	510407811

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1192212	O. Philippe Chambon	C/O New Leaf Ventures Times Square Tower, 7 Times Sq, Ste 3502 New York NY 10036	No	No	Yes	No
1247851	Ronald Hunt	C/O New Leaf Ventures Times Square Tower, 7 Times Sq, Ste 3502 New York NY 10036	No	No	Yes	No
1340806	K Vijay Lathi	C/O New Leaf Ventures 2500 Sand Hill Road, Suite 203 Menlo Park CA 94025	No	No	Yes	No
1441439	New Leaf Ventures Ii, L.p.	C/O New Leaf Ventures Times Square Tower, 7 Times Sq, Ste 3502 New York NY 10036	No	No	Yes	No
1441563	Jeani Delagardelle	C/O New Leaf Ventures 2500 Sand Hill Road, Suite 203 Menlo Park CA 94025	No	No	Yes	No
1441857	New Leaf Venture Management Ii, L.l.c.	C/O New Leaf Ventures Times Square Tower, 7 Times Sq, Ste 3502 New York NY 10036	No	No	Yes	No
1441858	New Leaf Venture Associates Ii, L.p.	C/O New Leaf Ventures Times Square Tower, 7 Times Sq, Ste 3502 New York NY 10036	No	No	Yes	No
1547100	Liam Ratcliffe	C/O New Leaf Ventures Times Square Tower, 7 Times Sq, Ste 3502 New York NY 10036	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-12-08	9,004	$6.05	1,671,471	No	4	S	Direct
Common Stock	Disposition	2014-12-09	70,081	$6.01	1,601,390	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price (net of commissions). These shares were sold in multiple transactions at prices ranging from $6.00 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management") is the general partner of NLV Associates. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi, and Liam Ratcliffe are the individual managers of NLV Management (the "Individual Managers"). NLV Associates and NLV Management disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his economic interest.
The price reported in Column 4 is a weighted average price (net of commissions). These shares were sold in multiple transactions at prices ranging from $6.00 to $6.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.